Medicine that’s
RIGHT FOR OUR PATIENTS
Azurity specializes in providing safe, high-quality treatments for patients requiring customized formulations for their care.
Medicine that’s
RIGHT FOR OUR PATIENTS
Azurity specializes in providing safe, high quality treatments for patients requiring customized formulations for their care. Azurity focuses on the needs of patients, such as children and the elderly, requiring customized, user-friendly drug formulations.
Medicine that’s
RIGHT FOR OUR PATIENTS
Azurity specializes in providing safe, high quality treatments for patients requiring customized formulations for their care. Azurity focuses on the needs of patients, such as children and the elderly, requiring customized, user-friendly drug formulations.
Medicine That’s Easy to Give…
and to Take
Azurity’s products have benefited millions of patients who are unable to swallow conventional oral dosage forms, such as tablets and capsules, and whose needs are not served by other commercially available therapies.
Azurity currently offers a comprehensive product portfolio that serves multiple therapeutic areas, with more on the way!
FDA-APPROVED ORAL LIQUIDS
A growing portfolio of products designed to fulfill unmet needs of both pediatric and elderly patients
FIRST® UNIT-OF-USE COMPOUNDING KITS
A family of prescription compounding kits designed as an alternative to conventional dosage forms
News & Events
Katerzia™, the First and Only Amlodipine Oral Suspension, 1 mg/mL, is Now Commercially Available for Pediatric Patients 6 Years of Age and Older
WOBURN, Mass. (September 25, 2019) – Azurity Pharmaceuticals, a specialty pharmaceutical company that makes safe, high-quality treatments for patients requiring customized formulations for their care, announced today that Katerzia (amlodipine) Oral Suspension, 1...
FDA Approves Katerzia™, the First and Only Amlodipine Oral Suspension, 1 mg/mL, for Pediatric Patients 6 Years of Age and Older
WOBURN, Mass. (July 10, 2019) – Azurity Pharmaceuticals, a specialty pharmaceutical company that makes safe, high-quality treatments for patients requiring customized formulations for their care, announced today that the U.S. Food and Drug Administration (FDA) has...
CutisPharma Announces Acquisition of Silvergate Pharmaceuticals, Name Change to Azurity Pharmaceuticals
WOBURN, Mass. (June 12, 2019) – CutisPharma, Inc. announced today its acquisition of Silvergate Pharmaceuticals, Inc. and the unveiling of its new corporate brand for the unified company: Azurity Pharmaceuticals. “I am thrilled to announce the combination of two...
Resources
Contact Us
Terms of Use | Privacy Policy and Policy on Cookies and other Tracking Technologies
All product imagery is for representation purposes only and may not include actual labels.
© 2019 Azurity Pharmaceuticals, Inc. All Rights Reserved.
